Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monocytes | 9 | 2024 | 275 | 2.250 |
Why?
|
| HIV Infections | 21 | 2024 | 2535 | 1.820 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2024 | 276 | 1.700 |
Why?
|
| Corynebacterium Infections | 1 | 2025 | 1 | 0.960 |
Why?
|
| Corynebacterium | 1 | 2025 | 2 | 0.960 |
Why?
|
| AIDS Dementia Complex | 2 | 2024 | 116 | 0.960 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 181 | 0.940 |
Why?
|
| HIV-1 | 7 | 2024 | 747 | 0.900 |
Why?
|
| Cross Infection | 1 | 2024 | 47 | 0.860 |
Why?
|
| Candidiasis | 1 | 2024 | 86 | 0.840 |
Why?
|
| Insulin Resistance | 3 | 2020 | 199 | 0.820 |
Why?
|
| Anti-HIV Agents | 7 | 2021 | 475 | 0.810 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 169 | 0.810 |
Why?
|
| Phylogeny | 1 | 2024 | 740 | 0.670 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 860 | 0.660 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 66 | 0.660 |
Why?
|
| Anti-Retroviral Agents | 3 | 2019 | 158 | 0.620 |
Why?
|
| Myeloid Cells | 1 | 2019 | 31 | 0.600 |
Why?
|
| Albuminuria | 2 | 2016 | 78 | 0.580 |
Why?
|
| Brain | 1 | 2024 | 1452 | 0.490 |
Why?
|
| Receptors, Immunologic | 3 | 2024 | 70 | 0.480 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.470 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2020 | 246 | 0.430 |
Why?
|
| Middle Aged | 17 | 2024 | 11819 | 0.350 |
Why?
|
| Atrophy | 2 | 2024 | 51 | 0.340 |
Why?
|
| Lymphocyte Activation | 5 | 2024 | 244 | 0.330 |
Why?
|
| Humans | 24 | 2025 | 42163 | 0.320 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 25 | 0.290 |
Why?
|
| Coronary Vessels | 2 | 2019 | 92 | 0.260 |
Why?
|
| Male | 17 | 2024 | 22779 | 0.250 |
Why?
|
| Female | 17 | 2024 | 24018 | 0.250 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 281 | 0.230 |
Why?
|
| Genome, Fungal | 1 | 2024 | 28 | 0.220 |
Why?
|
| Molecular Epidemiology | 1 | 2024 | 58 | 0.220 |
Why?
|
| Inflammation | 4 | 2018 | 729 | 0.220 |
Why?
|
| Hospitals | 1 | 2024 | 115 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 577 | 0.190 |
Why?
|
| Virus Latency | 2 | 2019 | 49 | 0.190 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 3077 | 0.180 |
Why?
|
| Receptors, CCR2 | 2 | 2018 | 28 | 0.180 |
Why?
|
| Genotype | 1 | 2024 | 796 | 0.180 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 379 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 35 | 0.170 |
Why?
|
| Fasting | 1 | 2020 | 56 | 0.170 |
Why?
|
| Interleukin-8 | 1 | 2020 | 74 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 74 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2020 | 80 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 344 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 56 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 112 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2020 | 165 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2019 | 146 | 0.150 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Galectins | 1 | 2019 | 29 | 0.150 |
Why?
|
| Cytokines | 2 | 2020 | 661 | 0.150 |
Why?
|
| E-Selectin | 1 | 2018 | 23 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 66 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2020 | 386 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Imidazoles | 1 | 2018 | 138 | 0.140 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 249 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 189 | 0.130 |
Why?
|
| Mitochondria | 1 | 2020 | 516 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2016 | 53 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 378 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 37 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2016 | 541 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2015 | 27 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2019 | 393 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 166 | 0.120 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 95 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 458 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 185 | 0.110 |
Why?
|
| Adult | 4 | 2024 | 13458 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 487 | 0.100 |
Why?
|
| Hippocampus | 1 | 2016 | 591 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2020 | 317 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 229 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2016 | 2485 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 729 | 0.080 |
Why?
|
| Hawaii | 3 | 2020 | 2004 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 84 | 0.060 |
Why?
|
| Aged | 1 | 2016 | 7982 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 661 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 774 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1020 | 0.050 |
Why?
|
| Autoantigens | 1 | 2021 | 85 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 30 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 253 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3942 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 107 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 84 | 0.040 |
Why?
|
| Virus Activation | 1 | 2019 | 38 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 17 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 68 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 203 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 115 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 143 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 122 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 164 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 708 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 197 | 0.030 |
Why?
|
| Virus Replication | 1 | 2019 | 318 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2018 | 164 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 57 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1266 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 599 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 733 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 200 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 61 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 57 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 139 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2018 | 324 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1416 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1574 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 411 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 246 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 1617 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 323 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 358 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 850 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 725 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 518 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2598 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 764 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 990 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2111 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 16695 | 0.010 |
Why?
|